GLP-1 drug plus hormone IUD for early endometrial cancer in obesity
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if adding a GLP-1 weight-loss drug to a hormone-releasing IUD can help treat very early endometrial cancer or a precancerous condition in women with obesity. The goal is to see if this combination is effective without surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed in the last 4 months with grade 1 endometrial cancer or a precancer called EIN (endometrioid intraepithelial neoplasia).
- Your body mass index (BMI) is 30 or higher (classed as obese).
- You either want to preserve your fertility or have other health problems that make surgery risky.
- You have not already started a GLP-1 drug more than 14 days ago, and you have not had a hormone IUD placed more than 45 days before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a weight-loss medication (tirzepatide) combined with a hormonal intrauterine device (IUD) to treat early-stage endometrial cancer or precancerous changes. The goal is to see if this approach can make the condition go away and possibly avoid more invasive surgery.
This study tests a weight-loss drug called tirzepatide (given as a shot) along with a progesterone-releasing intrauterine device (IUD) to treat early-stage endometrial cancer or a precancerous condition of the uterine lining. The goal is to see if this combination can reverse the abnormal cells without surgery, which may help women who are overweight or obese by addressing weight as a risk factor.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This trial tests a new treatment for very early endometrial cancer or a precancerous condition, aiming to help you avoid a hysterectomy and keep the chance of having children. It combines a medication (mazdutide) that helps with weight and hormone problems with a hormonal intrauterine device (LNG-IUS) to treat the lining of the womb.
This study compares two approaches for women with obesity and early-stage endometrial cancer: having surgery right away versus going through a special weight-loss and health-optimization program before surgery. The goal is to see if preparing the body before surgery improves outcomes.
This trial is testing whether a weight-loss medication called semaglutide combined with a hormonal intrauterine device (IUD) can help treat early-stage endometrial cancer or precancerous changes, allowing patients who want to preserve fertility or avoid surgery to do so. The study also includes a structured weight loss program.
Hear when a new Endometrioid Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.